Trends in hospitalization and mortality from rotavirus disease in New Zealand infants

Abstract

Current vaccines control severe disease, suggesting that 72% of cases reviewed would be eligible for prevention. A full cost effectiveness analysis is required to demonstrate anticipated benefits of vaccination.